Owner Aventis Pharmaceuticals Inc

Inventors Liu, Hong; Hahn, Chang

Agent Watermark

Pub. Number AU-B-2003230701

PCT Number PCT/US03/08590

PCT Pub. Number WO2003/083050

Priority 60/366,601 22.03.02 US; 0218518.9 09.08.02 GB

Filing date 21 March 2003

Wipo publication date 13 October 2003

Acceptance publication date 5 June 2008

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 14/435 (2006.01) Peptides having more than 20 amino acids - from animals

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C07K 19/00 (2006.01) Hybrid peptides

C12N 5/06 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines -

C12N 9/64 (2006.01) Enzymes, e.g. ligases (6.) - derived from animal tissue, e.g. rennin

C12N 15/87 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

C12Q 1/37 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving peptidase or proteinase

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids